NEW YORK, Dec. 14 (GenomeWeb News) - Fisher Biosciences, through its HyClone business, will partner with Alfa Laval to provide Haemacure with single-use bioprocessing systems, the company said today.
The bioprocessing systems are marketed and sold by Alfa Laval under an exclusive agreement with HyNetics, a three-year joint venture between HyClone and Alfa Laval.
The systems will be installed in Haemacure's Sarasota, Fla. manufacturing facility for Hemaseel biological adhesives. This will be one of the first major installations of HyNetics technology for large-scale bioprocessing.
Under the agreement, Alfa Laval will provide all of the detailed engineering for the facility as well as select the production equipment. The core bioprocessing equipment will be the HyNetics single-use mixing technology.
HyClone will provide Haemacure with its proprietary disposable BioProcess Containers as well as other disposable components that complement the HyNetics system.
The disposable bioprocessing system will allow Haemacure to "establish and operate a very cost-efficient facility," said Marc Paquin, Haemacure's president and chief executive officer, in a statement.
Financial details were not disclosed.